Schemes & Policies

Revised Drugs, Medical Devices and Cosmetics Bill Faces Industry Opposition

11 August 2026UPSCSSC

In Brief

Pharma and medical device sectors raise concerns over proposed reforms in the draft Drugs, Medical Devices and Cosmetics Bill.

The Union Government's ongoing initiative to overhaul India's decades-old drug regulation architecture encountered resistance as pharmaceutical and medical device sector representatives submitted critical feedback on the proposed Drugs, Medical Devices and Cosmetics Bill. Industry stakeholders argued that crucial recommendations had been overlooked, leaving core provisions similar to previously deferred drafts.

India's pharmaceutical regulatory framework currently relies on the historical Drugs and Cosmetics Act of 1940. Given the expansion of modern bio-pharmaceuticals, clinical trial frameworks, medical technology, and e-pharmacies, a comprehensive updating of legislation has been under drafting since 2022 to replace archaic regulatory clauses.

This update touches upon Public Health, Intellectual Property Rights, and Regulatory Governance in GS Paper II and Paper III. Students should study the regulatory role of CDSCO, Central Drugs Standard Control Organization, and challenges in maintaining global quality compliance.

UPSC Study NotesHIGHGS2 — Governance & Public Health / GS3 — Economy

GS2 — Governance & Public Health / GS3 — Economy

📌 Exam Angle

Mains can evaluate how overhauling the 1940 legislation balances public health safety with pharmaceutical innovation. Prelims may test the statutory mandate of CDSCO, provisions distinguishing medical devices from traditional pharmaceuticals, and regulations governing e-pharmacies and clinical trials.

⚠️ Key Concerns

Industry stakeholders worry that excessive criminalization and rigid oversight could stifle domestic R&D and med-tech innovation. Crucial gaps persist regarding clear rules for e-commerce pharmacies and establishing a fully independent regulatory framework for medical devices.

💡 Why It Matters

As the global "Pharmacy of the World," India needs a modern, internationally compliant regulatory architecture to guarantee drug quality and safeguard public health. Replacing archaic colonial-era legislation is essential to attract foreign investment and scale up bio-pharmaceutical manufacturing.

🔑 Must Remember

• Replaces the archaic Drugs and Cosmetics Act of 1940 to modernize India's regulatory framework. • Introduces distinct regulatory provisions for medical devices versus traditional pharmaceutical drugs. • CDSCO serves as the apex national regulatory authority under the Ministry of Health and Family Welfare.

📝 Key Terms

CDSCODrugs and Cosmetics Act 1940Spurious DrugsBio-pharmaceuticalsMedical Devices RulesE-pharmaciesCentral Licensing AuthorityRegulatory Governance

Revised Drugs, Medical Devices and Cosmetics Bill Faces Industry Opposition

More in Schemes & Policies